Application/Control No.

O9/454,481

Examiner

Stephen L. Rawlings, Ph.D.

Applicant(s)/Patent Under Reexamination ALLISON ET AL.

Art Unit

Page 1 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classif	ication
	Α	US-5,811,097-A	09-1998	Allison, JP, etal	424	144.1
	В	US-5,855,887-A	01-1999	Allison, JP, et al	424	144.1
	O	US-6,051,227-A	03-2000	Allison, JP, et al	424	144.1
	D	US				
	E	US				•
	F	US				
	G	US				
	Н	US				
	ı	US				
	j	US				
	ĸ	US				
	L	US				
	М	US				<u> </u>

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	s					
	Т					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
+	U	Bodey, B, et al, Failure of cancer vaccines: the significant limitations of this approach to immunotherapy, Anticancer Research, vol. 20, pp. 2665-2676
,	V	Timmerman, JM, et al, 1999, Dendritic cell vaccines for cancer immunotherapy, Annual Review of Medicine, vol. 50, pp. 507-529
¢	w	Arceci, RJ, 1998, The potential for antitumor vaccination in acute myelogenous leukemia, Journal of Molecular Medicine, vol. 76, pp. 80-93
ò	х	Pardoll, DM, 1993, Cancer vaccines, Immunology Today, vol. 14, pp. 310-316

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001) | Manuary | SR 5/18/01

Application/Control No.

O9/454,481

Applicant(s)/Patent Under Reexamination ALLISON ET AL.

Examiner

Stephen L. Rawlings, Ph.D.

Applicant(s)/Patent Under Reexamination ALLISON ET AL.

Page 2 of 5

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	А	US			
	В	US			
	С	US			
	D	US			
	E	US			
	F	US			
	G	US			
	Н	US			
	1	US			
	J	US			
	к	US			
	L	US			
	М	US			

FOREIGN PATENT DOCUMENTS

*		Cour	Document Number htry Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	-	•				
	0	-	-				
	Р	_	-				
	α	-	-				
	R	-	-				
	s	_	•				
	Т	-	-				

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
ſ	U	Lee, K-H, et al, 1999, Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, Journal of Immunology, vol. 163, pp. 6292-6300
Ū	٧	Zaks, TZ, et al, 1998, Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors, Cancer Research, vol. 58, pp. 4902-4908
•	w	Zhu, J, et al, 2001, Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade enhances incidence and severity of experimental autoimmune neurtitis in resistant mice, Journal of Neuroimmunology 115: 111-117
4	х	Yang, Y-F, et al, 1997, Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages, Cancer Research, vol. 57, pp. 4036-4041

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

SR 5/18/01

Application/Control No.

Applicant(s)/Patent Under Reexamination ALLISON ET AL.

09/454,481 Examiner

Stephen L. Rawlings, Ph.D.

Art Unit 1642

Page 3 of 5

U.S. PATENT DOCUMENTS

				U.S. PATERT DOCUMENTS	
*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US			
	В	US			
	С	US			
	D	US			
	Е	US			
	F	US			
	G	US			
	Н	US			
·	ı	US			
	J	US			
	К	US			
	L	US			
	М	US			
					<u> </u>

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	σ					
	R					
	S	-				
	Т					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
Ĺ	U	Anderson, DE, et al, 2000, Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population, Nature Medicine, vol. 6, pp. 211-214
3	V	Leach, DR, et al, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science, vol. 271, pp. 1734-1736
,	w	Chambers, CA, et al, 1997, Thymocyte development is normal in CTLA-4-deficient mice, Proceedings of the National Academy of Sciences USA, vol. 94, pp. 9296-9301
	х	Gribben, G, et al, 1994, Alloantigen and concomitant CTLA4 signaling induces clonal deletion of alloreactive T cells, Blood, vol. 84, pp. 397a (meeting abstract)

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Application/Control No. Applicant(s)/Patent Under Reexamination 09/454,481 ALLISON ET AL. Art Unit Examiner Page 4 of 5 Stephen L. Rawlings, Ph.D. 1642

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US			
	В	US			
	С	US			
	D	US			
	Ε	US			
	F	US			
	G	US			
	н	US			
	-	US			
	j	US			
	К	US			
	L	US			
	М	US			


FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	s	-				
	Т	-				

NON-PATENT DOCUMENTS

		NON-FATENT DOCUMENTS
*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
5	υ	Lewis, GD, et al, 1996, Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness, Cancer Research, vol. 56, pp. 1457-1465
	v	Gao, P, et al, Tumor vaccination that enhances antitumor T-cell responses does not inhibit the growth of established tumors in combination with interleukin-12 treatment, Journal of Immunotherapy, vol. 23, pp. 643-653
r	w	Sullivan, TJ, et al, 1998, Induction of CNS inflammatory disease as a consequence of CTLA-4/B7 blockade, FASEB Journal, vol. 12, pp. A1092 (meeting abstract)
•	х	Sotomayor, EM, et al, 1999, In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance, Proceedings of the National Academy of Science USA, vol. 96, pp. 11476-11481

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.



U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

Application/Control No. Applicant(s)/Patent Under Reexamination 09/454,481 ALLISON ET AL. Notice of References Cited Examiner Art Unit Page 5 of 5 Stephen L. Rawlings, Ph.D. 1642

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US			
·	В	US			
	С	US			
	D	US			
	E	US			
	F	US			
	G	US			
	Н	US			
	_	US			
	7	US			
	К	US			
	L	US			
	М	US			


FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification	
	N						
	0						
	Р						
	Q						
	R						
	s						
	Т						

NON-PATENT DOCUMENTS

		NON-FATENT DOCUMENTS
*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
į	U	Christadoss, P, et al, 2000, Animal models of myasthenia gravis, Clinical Immunology, vol. 94, pp. 75-87
,	V	Sussman, JJ, et al, 1994, Activation of T lymphocytes for the adoptive immunotherapy of cancer, Annals of Surgical Oncology, vol. 1, pp. 296-306 (abotract only), MEDLINE
t	w	Heslop, HE, 1994, Cytokine gene transfer in the therapy of malignancy, Baillieres Clinical Haematology, vol. 7, pp. 135-51 (abstract only), MEDLINE 8038497
o	х	Wallack, MK, et al, 1992, Active specific immunotherapy with vaccinia melanoma oncolysate, Mt. Sinai Journal of Medicine, vol. 59, pp. 227-233 (abstract only), MEDLINE 1318507

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.



U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

Application/Control No.

O9/454,481

Examiner

Applicant(s)/Patent Under Reexamination ALLISON ET AL.

Art Unit

Page 6 of 6

1642

U.S. PATENT DOCUMENTS

Stephen L. Rawlings, Ph.D.

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classif	ication
	А	US				
	В	US				
	С	US				
	D	US				
	Ε	US				
	F	US				
	G	US				
	Н	US				
	1	US				
_	J	US				
	К	US				
	L	US				
	М	US				

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification	
	N						
	0						
	Р						
	Q						
	R						
	S						
	Т						

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
ŧ	υ	Krummel, MF, et al, 1996, Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo, Internation Immunology, vol. 8, pp. 519-523 (abstract only), BIOSIS 1996.283884
'n.	٧	Walunas, TL, et al, 1994, CTLA-4 can function as a negative regulator of T cell activation, Immunity, vol. 1, pp. 405-413
!	w	Kearney, ER, et al, 1995, Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cell in vivo is dependent on CD28 costimulation and inhibited by CTLA-4, Journal of Immunology, vol. 155, pp. 1032-1036
	х	

*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

